Halley E. Gilbert - 05 Jun 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 21:20:56 UTC
Prior SEC filing: 21 Nov 2025
Next SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/Latha Vairavan, as Attorney-in-Fact for Halley E. Gilbert

Key filing fact

Halley E. Gilbert filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 09 Jun 2026.

Key facts

This page summarizes Halley E. Gilbert's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 21:20.

Change

Previous filing in this sequence was filed on 21 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001601360 Primary reporting owner

Gilbert Halley E

Relationship: Director
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/Latha Vairavan, as Attorney-in-Fact for Halley E. Gilbert
Signature date: 09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Award

Transaction value
Shares: +5,778
Change %: +26%
Price: $0.000000^*
Shares after: 27,901
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +16,667
Change %
Price: $0.000000^*
Shares after: 16,667
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,667
Exercise price: $21.23
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Footnote F2

The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.